Study: Synthetic protein potentially improves outcomes for certain subgroups following intracerebral hemorrhage
February 4, 2026
The University of Cincinnati’s Joseph Broderick, MD, presented results from the FASTEST trial at the International Stroke Conference, simultaneously published in The Lancet, that found administering a synthetic protein, recombinant Factor VIIa, can reduce bleeding and potentially improve outcomes for certain patients at the highest risk of continued bleeding following an intracerebral hemorrhage.